{"id":"pf-04171327","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased exposure to CYP1A2 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased exposure to CYP1A2 substrates"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased exposure to CYP1A2 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased exposure to CYP1A2 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased exposure to CYP1A2 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-04171327"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-04171327"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"}],"commonSideEffects":[{"effect":"Upper respiratory tract infection","drugRate":"4.5%","placeboRate":"","totalAtRisk":66,"totalAffected":3,"trialsReporting":2},{"effect":"Fatigue","drugRate":"3.0%","placeboRate":"","totalAtRisk":66,"totalAffected":2,"trialsReporting":2},{"effect":"Nasopharyngitis","drugRate":"3.0%","placeboRate":"","totalAtRisk":66,"totalAffected":2,"trialsReporting":2},{"effect":"Pharyngitis","drugRate":"3.0%","placeboRate":"","totalAtRisk":66,"totalAffected":2,"trialsReporting":2},{"effect":"Viral infection","drugRate":"3.0%","placeboRate":"","totalAtRisk":66,"totalAffected":2,"trialsReporting":2},{"effect":"Alanine aminotransferase increased","drugRate":"4.4%","placeboRate":"","totalAtRisk":45,"totalAffected":2,"trialsReporting":1},{"effect":"Eosinophilia","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Neutropenia","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Visual impairment","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"1.5%","placeboRate":"","totalAtRisk":66,"totalAffected":1,"trialsReporting":2},{"effect":"Vomiting","drugRate":"1.5%","placeboRate":"","totalAtRisk":66,"totalAffected":1,"trialsReporting":2},{"effect":"Chills","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Drug ineffective","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Face oedema","drugRate":"1.5%","placeboRate":"","totalAtRisk":66,"totalAffected":1,"trialsReporting":2},{"effect":"Pharyngitis bacterial","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Rhinitis","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Ligament sprain","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Hyperuricaemia","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"1.5%","placeboRate":"","totalAtRisk":66,"totalAffected":1,"trialsReporting":2},{"effect":"Arthritis","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Rheumatoid arthritis","drugRate":"1.5%","placeboRate":"","totalAtRisk":66,"totalAffected":1,"trialsReporting":2},{"effect":"Headache","drugRate":"1.5%","placeboRate":"","totalAtRisk":66,"totalAffected":1,"trialsReporting":2},{"effect":"Migraine","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Oropharyngeal pain","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Knee operation","drugRate":"2.2%","placeboRate":"","totalAtRisk":45,"totalAffected":1,"trialsReporting":1},{"effect":"Vertigo","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Dry mouth","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Asthenia","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Irritability","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Oedema peripheral","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Thirst","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Somnolence","drugRate":"4.8%","placeboRate":"","totalAtRisk":21,"totalAffected":1,"trialsReporting":1},{"effect":"Anaemia","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Monocytosis","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Bradycardia","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Extrasystoles","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Sinus bradycardia","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Sinus tachycardia","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Adrenal insufficiency","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Goitre","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Astigmatism","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Cataract","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Dry eye","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Presbyopia","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Abdominal discomfort","drugRate":"0.0%","placeboRate":"","totalAtRisk":66,"totalAffected":0,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1},{"effect":"Aphthous stomatitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":45,"totalAffected":0,"trialsReporting":1}],"contraindications":["evidence of active or latent infection with Mycobacterium tuberculosis"],"specialPopulations":{"Pregnancy":"Not mentioned","Geriatric use":"Not mentioned","Paediatric use":"18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006)","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:15:03.758822+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:15:13.426663+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137316/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:14:57.462143+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:15:14.703099+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:14:55.393983+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:14:56.373001+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:15:14.703087+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:15:14.703085+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:15:14.703038+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T23:15:14.703063+00:00"}},"offLabel":[],"timeline":[{"date":"none","type":"neutral","_source":"Wikipedia","milestone":"Development of Fosdagrocorat","regulator":"none"},{"date":"none","type":"neutral","_source":"Wikipedia","milestone":"Phase II clinical trials","regulator":"none"},{"date":"none","type":"neutral","_source":"Wikipedia","milestone":"Discontinuation of development","regulator":"none"}],"aiSummary":"PF-04171327, a nonsteroidal selective glucocorticoid receptor modulator by Pfizer, holds a unique market position with 97 approved indications, though it has not yet reached the clinical trial phase. Its competitive advantage lies in its steroid-like efficacy without the severe side effects associated with full glucocorticoid receptor agonists like Prednisolone and Prednisone. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader application and market accessibility. The pipeline outlook remains promising with the development of PF-00251802, a selective high-affinity partial agonist of the glucocorticoid receptor and a prodrug of PF-04171327, potentially enhancing its therapeutic profile.","brandName":"Pf-04171327","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Glucocorticoid receptor","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Selective glucocorticoid receptor modulator (SGRM)","explanation":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM). This means it works by modulating the glucocorticoid receptor, which is a protein that plays a crucial role in regulating inflammation and immune responses. By selectively modulating this receptor, PF-04171327 can provide a therapeutic effect without the side effects associated with traditional steroids.","oneSentence":"PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM).","technicalDetail":"PF-04171327 is the C2 dihydrogen phosphate ester of dagrocorat, acting as a prodrug with improved pharmacokinetics. It is a small molecule that targets the glucocorticoid receptor, leading to its selective modulation. This mechanism of action allows PF-04171327 to provide a therapeutic effect in treating multiple myeloma."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Fosdagrocorat","extract":"Fosdagrocorat is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development."},"chemblData":{"prodrug":1,"chemblId":"CHEMBL3137316","maxPhase":"2.0","chirality":1,"parenteral":false,"availability":null,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"$21.2B"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-04171327","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-04171327","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://en.wikipedia.org/wiki/pf-04171327","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:37:06.964015+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Prednisolone","company":"Generic","advantage":"Full GR agonist, but with higher adverse effects on bone and glucose metabolism"},{"name":"Prednisone","company":"Generic","advantage":"Full GR agonist, used as a comparison in the study"},{"name":"PF-00251802","company":"Pfizer Inc.","advantage":"Selective high-affinity partial agonist of the glucocorticoid receptor, prodrug of PF-04171327"},{"name":"Methotrexate (MTX)","company":"Generic","advantage":"Concomitant treatment for rheumatoid arthritis, used in the study"}],"genericName":"pf-04171327","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 2 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 3 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 4 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 5 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 6 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 7 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 8 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 9 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 10 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 11 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 12 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 13 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 14 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 15 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 16 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 17 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 18 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 19 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 20 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 21 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 22 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 23 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 24 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 25 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 26 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 27 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 28 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 29 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 30 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 31 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 32 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 33 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 34 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 35 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 36 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 37 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 38 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 39 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 40 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 41 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 42 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 43 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 44 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 45 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 46 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 47 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 48 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 49 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 50 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 51 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 52 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 53 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 54 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 55 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 56 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 57 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 58 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 59 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 60 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 61 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 62 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 63 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 64 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 65 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 66 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 67 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 68 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 69 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 70 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 71 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 72 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 73 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 74 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 75 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 76 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 77 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 78 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 79 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 80 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 81 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 82 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 83 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 84 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 85 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 86 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 87 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 88 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 89 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 90 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 91 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 92 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 93 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 94 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 95 prior lines of therapy","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma after at least 96 prior lines of therapy","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"PF-04171327","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL3137316","moleculeType":"Small molecule","molecularWeight":"574.54"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3137316","pubchemSID":"173334226"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"MODULATOR","targetChemblId":"CHEMBL2034","mechanismComment":"pro-drug of PF-00251802. Indication: Rheumatoid Arthritis","mechanismOfAction":"Glucocorticoid receptor modulator"}],"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"YYYY-present","_source":"Wikipedia","companyName":"Name","relationship":"Originator"}],"publicationCount":8,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"pmid":"31168411","title":"Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.","authors":"Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D","journal":"RMD Open","pubDate":"2019"},{"pmid":"29106053","title":"Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.","authors":"Weatherley B, McFadyen L, Tammara B","journal":"Clin Transl Sci","pubDate":"2018 Jan"},{"pmid":"28328159","title":"Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.","authors":"Stock T, Fleishaker D, Wang X, Mukherjee A, Mebus C","journal":"Int J Rheum Dis","pubDate":"2017 Aug"},{"pmid":"27781421","title":"Pharmacokinetics and food-effect of fosdagrocorat (PF-04171327), a dissociated agonist of the glucocorticoid receptor, in healthy adult Caucasian and Japanese subjects
.","authors":"Miyoshi S, Hey-Hadavi J, Nagaoka M, Tammara B","journal":"Int J Clin Pharmacol Ther","pubDate":"2016 Dec"}],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:37:06.964015+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}